On August 14, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 126) describing the following changes to the Common Drug Review (CDR) process. Extended Initiation Range for December 2017 CDEC Meeting CADTH has extended the initiation range for Common ...
On July 13, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 124) describing the following changes. CDEC Meeting Added in December 2017 and Updated CDEC Meeting Dates CADTH will be holding a Canadian Drug Expert Committee (CDEC) meeting in December 2017 ...
On June 9, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 122) describing the following changes. 1. Revised Advanced Notification Process for CADTH Common Drug Review Drugs Undergoing Expedited Health Canada Review Effective immediately, the mandatory advance notification requirement for drugs that are ...
CADTH’s Updated Guidelines for the Economic Evaluation of Health Technologies – 4th Edition Now Available
The updated guidelines recognize the substantial advances that have been made in the methods of economic evaluation and they offer up-to-date guidance on the best practices for determining the economic value of health technologies. Available for download at the following link.
New CADTH Processes Expanding CADTH’s Drug Review Processes to Include Radiopharmaceuticals In collaboration with the participating jurisdictions, CADTH is pleased to announce that they will accept submissions for Radiopharmaceutical Submissions and Other Process Alignment Implementations effective April 1, 2017. Applicants/Submitters planning to file a submission or resubmission for a radiopharmaceutical on ...
CADTH is hosting an online or in person event on Tuesday, March 28, 2017 to release the fourth edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. The Guidelines are intended to help produce credible and standardized economic information that is relevant and useful to decision-makers in Canada’s ...
CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian ...
The Canadian Association for Healthcare Reimbursement (CAHR) is hosting Market Access 201-Fundamentals of Reimbursement in Canada. This one-day training course is a continuation of Market Access 101 and offers a deeper dive into Market Access strategies. The program will be emceed by Dr. Jeffery Hoch from the Department of ...
Effective immediately, CADTH will be formally engaging with the pan-Canadian Pharmaceutical Alliance (pCPA) and will be including the pCPA office in the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) processes. This will provide an opportunity for the pCPA office to receive relevant information on drugs reviewed ...
CADTH Releases Recommendations Report for Anti-Vascular Endothelial Growth Factor Drugs for Retinal Conditions
On May 5, 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Recommendations Report on its project on Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Retinal Conditions. CADTH has undertaken a therapeutic review comparing the clinical effectiveness and relative cost of three anti-VEGF drugs (aflibercept, bevacizumab, ranibizumab) ...